The rate of COVID-19 associated hospitalization among children aged 5 to 11 is just 0.0008%. In real-world terms, that’s so close to zero you basically cannot lower it any further.
Despite that, the U.S. Food and Drug Administration’s vaccine advisory panel — the Vaccines and Related Biological Products Advisory Committee (VRBPAC) — on June 15, 2022, unanimously approved to grant Emergency Use Authorization (EUA) to Pfizer’s and Moderna’s COVID shots for infants and young children.
… The drug companies need this last remaining age group to be included under the EUA, because once the emergency is nally declared “over,” the next phase of liability shielding requires that the shots receive approval by the CDC’s Advisory Committee on Immunization Practices (ACIP). Once the vaccine is on the childhood vaccination schedule, the vaccine makers are permanently shielded from liability for injuries and deaths that occur in any age group, including adults